home / stock / nxtc / nxtc articles
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%...
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discov...
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discov...
U.S. stocks traded higher this morning, following the release of economic reports on Thursday. Following the market opening Thursday, the Dow trade...
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discove...
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discove...
News, Short Squeeze, Breakout and More Instantly...
NextCure Inc. Company Name:
NXTC Stock Symbol:
NYSE Market:
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...